Nuclea Raises $4.48 Million in Convertible Note Financing & Secures New, Strategic U.S. Patent

April 9, 2014

Pittsfield, MA – Nuclea Biotechnologies, Inc. today announced that it has completed $4,481,250 million in convertible note financing.  The notes mature in October 2014 and are convertible into the Company’s convertible preferred securities.  The new funds have been raised to finance the Wilex Inc. acquisition and ongoing manufacturing and marketing activities.

Since its creation in 2005, Nuclea has raised at total of $45.7 million. The Pittsfield-based company is focused on the development, clinical validation, and commercialization of novel diagnostic and prognostic assays.

“This is an extremely exciting time for Nuclea,” said Patrick Muraca, President & CEO of Nuclea. “We have entered the commercialization stage and are building the infrastructure for that to be as successful as our development stage. Commercialization requires a push in manufacturing and marketing, so that is currently our focus.”

Additionally, today Nuclea secured a new US Patent No. 8,685,891 B2 covering a method for monitoring the progression of cancer by assaying the expression of Fatty acid Synthase (FAS) from a biological sample of the cancer patient. The patent utilizes a proprietary anti-FAS antibody developed by Nuclea. The patent protects an antibody that is a key component to all of Nuclea’s FAS tests.

This is another step in Nuclea’s development of FAS-based clinical diagnostics that advance the understanding of how cancer progresses, and its goal of developing products that convey important information to clinicians that help them provide effective treatment to their patients.

Building on the news of the FAS patent, last weekend Nuclea presented a poster, Permanent Abstract Number 4332, at the American Association for Cancer Research’s Annual Meeting. Their poster was topic was Diagnostic applications of FAS monoclonal antibodies.

Nuclea Biotechnologies, Inc. -- is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries. http://www.nucleabio.com

###

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.